Related Experiment Video
Updated: Mar 31, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Association between inhaled corticosteroids and anti-PD-1/PD-L1 efficacy in patients with NSCLC with concurrent COPD
Lili Zheng1,2, Fangwen Wang3, Hui Zhou2
1School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400045, China.
Abstract:
Patients with non-small cell lung cancer (NSCLC) and comorbid chronic obstructive pulmonary disease (COPD) may exhibit enhanced sensitivity to programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors. However, whether inhaled corticosteroids (ICS) use for COPD maintenance influences this response remains unclear. We retrospectively analyzed 222 such patients stratified by COPD maintenance regimen into ICS-containing (ICS group) and non-ICS (N-ICS group) cohorts. After propensity score matching, patients receiving ICS demonstrated significantly prolonged progression-free survival (PFS), higher overall response rate (ORR) and disease control rate (DCR), and comparable immune-related adverse events (irAEs). Multivariable analysis confirmed ICS as an independent predictor for prolonged PFS. Subgroup analyses further revealed that baseline neutrophil-lymphocyte ratio (NLR) ≤ 3.36 and lactate dehydrogenase (LDH) ≤ 240 U/L were consistently associated with longer PFS, regardless of ICS use. In conclusion, ICS-containing regimens are associated with enhanced response to PD-1/PD-L1 inhibitors in patients with NSCLC with COPD, without compromising safety.
More Related Videos
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction

